- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05062421
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis. (Arthritis)
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).
These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).
The drugs to be administered to patients are:
- JAK-type kinase inhibitors.
- Monoclonal antibodies against TNF.
- Soluble receptor against TNF.
- Biosimilar FAMEb.
- Rituximab.
- Abatacept.
- Drugs that block IL6.
A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Carlos García Pérez
- Telefonnummer: 955 04 31 27
- E-post: administración.eecc.hvm.sspa@juntadeandalucia.es
Studer Kontakt Backup
- Navn: Blanca Estela Hernández Cruz
- Telefonnummer: 955008000
- E-post: blancahcruz@gmail.com
Studiesteder
-
-
-
Sevilla, Spania, 41009
- Rekruttering
- Hospital Universitario Virgen Macarena
-
Ta kontakt med:
- Blanca Estela Hernández Cruz
- Telefonnummer: 955008000
- E-post: blancahcruz@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients aged ≥18 years.
- With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
- Who have received at least one of the doses of the study drugs.
- In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
- With at least two complete evaluations (baseline and final) of clinical variables.
Exclusion Criteria:
- Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
- Patients in whom more than 50% of the variables to be collected are missing in the data collection.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Cases 1
Patients treated with JAK-type kinase inhibitors.
|
Cases 2
Patients treated with monoclonal antibodies against TNF.
|
Cases 3
Patients treated with soluble receptor against TNF.
|
Cases 4
Patients treated with FAME group biosimilars.
|
Cases 5
Patients treated with rituximab.
|
Cases 6
Patients treated with abatacept.
|
Cases 7
Patients treated with drugs that block the IL6.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Survival study
Tidsramme: Up to 60 weeks
|
To know the survival at 12, 24, 48, 60, 72 and 84 months to the synthetic directed anti-rheumatic drugs, disease modifiers (FAMEsd) and the biological disease modifying anti-rheumatic drugs (FAMEb) in patients with rheumatoid arthritis treated in routine.
|
Up to 60 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Study of clinical characteristics.
Tidsramme: Up to 60 weeks
|
To know the sociodemographic and clinical characteristics of the patients who receive FAMEsd and FAMEb in routine clinical practice at the HUVM.
|
Up to 60 weeks
|
Measure of the influence of comorbidities.
Tidsramme: Up to 60 weeks
|
To assess the influence of comorbidities on drug persistence.
|
Up to 60 weeks
|
Number of participants who discontinued treatment due to serious adverse effects.
Tidsramme: Up to 60 weeks
|
Failure due to serious adverse events, adverse events of special interest, emerging adverse events and minor adverse events that require discontinuation of the drug.
|
Up to 60 weeks
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Blanca Estela Hernández Cruz, Hospital Universitario Virgen Macarena
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FIS-FME-2020-01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .